South East London Area Prescribing Committee
Formulary recommendation

Reference	**019**
Intervention:	**Vesomni® 6 mg/0.4 mg (solifenacin/tamsulosin) modified release tablet** (Vesomni is a fixed dose combination tablet consisting of the anticholinergic solifenacin and the alpha blocker tamsulosin)
Date of Decision	**October 2017**
Date of Issue:	**November 2017**
Recommendation:	**Grey – not recommended for prescribing in South East London**
Further Information	The South East London Area Prescribing Committee has reviewed its original formulary decision for Vesomni issued in December 2014. This recommendation updates the original formulary decision. The Committee is no longer able to support the use of Vesomni for the management of lower urinary tract symptoms (LUTS) in men in line with its licence*. This is because as per the original formulary decision a pathway for LUTs that outlines Vesomni's place in therapy has not been finalised in line with the timescales requested by the Committee. Vesomni will be grey listed until a finalised pathway is received from local clinicians in South East London. **No new patients should be started on Vesomni from the issue date of this updated recommendation.** *Vesomni is licensed for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy.
Shared Care/Transfer of care document required:	N/A
Cost Impact for agreed patient group	N/A
Usage Monitoring & Impact Assessment	Trusts – monitor non-formulary requests CCGs – monitor epact data and exception reports from GPs if inappropriate requests to prescribe are made to primary care.
Evidence reviewed	N/A

NOTES:

a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if a submission is received or new NICE guidelines or technology appraisals are issued.
c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS**